3Q12 US Copaxone sales were $775M; US sales of Copaxone for the first 9 months of 2012 were $2.09B, ahead of the pace to meet my estimate of $2.6B for the full year (#msg-75932272).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”